Premium
CAR‐T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph + mixed phenotype acute leukaemia with minimal residual disease
Author(s) -
Kong Danqing,
Qu Changju,
Dai Haiping,
Li Zheng,
Yin Jia,
Chen Suning,
Kang Liqing,
Chen Guanghua,
Zhu Mingqing,
Yu Lei,
Wu Depei,
Tang Xiaowen
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16982
Subject(s) - medicine , blinatumomab , minimal residual disease , philadelphia chromosome , transplantation , oncology , immunology , chimeric antigen receptor , hematopoietic stem cell transplantation , immunotherapy , cancer research , cd19 , antigen , leukemia , cancer , chromosomal translocation , biology , gene , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom